Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke's website at BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 3, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:
2024年6月3日，马萨诸塞州贝德福德——(美国商业资讯)——生物技术公司Stoke Therapeutics，Inc。（Nasdaq：STOK）致力于通过上调基于RNA的药物的蛋白质表达来解决严重疾病的潜在原因，今天宣布公司管理层将在以下即将举行的投资者会议上进行演讲：
Goldman Sachs 45th Annual Global Healthcare Conference
Date: Monday, June 10, 2024
Time: 4:00 p.m. ET
高盛第45届全球保健大会
日期：2024年6月10日星期一
时间：东部时间下午4:00
TD Cowen Genetic Medicines & RNA Summit
Date: Thursday, June 20, 2024
Time: 10:00 a.m. ET
TD Cowen遗传药物和RNA峰会
日期：2024年6月20日星期四
时间：东部时间上午10:00
Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/.
每个事件的现场网络广播和网络广播的存档重播将在Stoke网站的投资者和新闻部分上提供，网址为https://investor.stoketherapeutics.com/。.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke's first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.
关于Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK) 是一家专注于通过上调基于RNA的药物的蛋白质表达来解决严重疾病的生物技术公司。 使用Stoke专有的TANGO(有针对性的核基因输出增强)方法，Stoke正在开发选择性恢复蛋白质水平的反义寡核苷酸(ASOs)。Stoke的第一个化合物STK-001正在进行临床试验，用于治疗Dravet综合症，一种严重和渐进的遗传性癫痫。 Dravet综合症是许多疾病之一，这些疾病是由于半数失衡引起的，其中失去正常蛋白质水平的约50％会导致疾病。 Stoke正在追求开发STK-002，用于治疗常染色体显性视神经萎缩(ADOA)，这是最常见的遗传性视神经病变。 Stoke的初始重点是半数失衡症和中枢神经系统和眼睛疾病，尽管已经在其他器官、组织和系统中证明了其专有方法的广泛潜力，支持其广阔的潜力。 Stoke的总部位于马萨诸塞州贝德福德，另设办事处于马萨诸塞州剑桥市。 有关更多信息，请访问https://www.stoketherapeutics.com/。.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603791457/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240603791457/en/
Stoke Investor Contact:
Eric Rojas
Vice President, Investor Relations
IR@stoketherapeutics.com
617-312-2754
Stoke投资者联系人：
Eric Rojas
投资者关系副总裁
IR@stoketherapeutics.com
617-312-2754
Source: Stoke Therapeutics, Inc.
资料来源：Stoke Therapeutics，Inc。